Trial Profile

A Phase 1, First-in-Human, Open-Label Study to Evaluate the Safety, Tolerability, PK, and Preliminary Anti-tumor Activity of the Novel Orally Available CDK2 Inhibitor NKT3447 in Adults With Advanced/Metastatic Solid Tumors

Status: Active, no longer recruiting

Phase of Trial: Phase I

Latest Information Update: 14 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs NKT 3447 (Primary)
Indications Advanced breast cancer; Endometrial cancer; Gastric cancer; HER2 negative breast cancer; Oesophageal cancer; Ovarian cancer; Small cell lung cancer; Solid tumours; Triple negative breast cancer
Focus Adverse reactions; First in man; Therapeutic Use
Sponsors NiKang Therapeutics

11 Mar 2025 Status changed from recruiting to active, no longer recruiting.
20 Jan 2025 Planned End Date changed from 1 Mar 2025 to 1 Mar 2027.
20 Jan 2025 Planned primary completion date changed from 1 Mar 2025 to 1 Nov 2025.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com